Who are MMF/EC-MPS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate mofetil Tab./Cap., Mycophenolic Acid (Myfortic), Mycophenylate mofetil, Mycophenolic Acid Oral Product, Placebo to Mycophenolate mofetil, Mycophenolic Acid (MPA).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmf-ec-mps.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MMF/EC-MPS — Competitive Intelligence Brief

MMF/EC-MPS (MMF/EC-MPS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant; IMPDH inhibitor. Area: Immunology; Transplantation.

marketed Immunosuppressant; IMPDH inhibitor Inosine monophosphate dehydrogenase (IMPDH) type II Immunology; Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

MMF/EC-MPS (MMF/EC-MPS) — Novartis. MMF/EC-MPS is an inosine monophosphate dehydrogenase (IMPDH) inhibitor that selectively suppresses T and B lymphocyte proliferation to prevent organ rejection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
MMF/EC-MPS TARGET	MMF/EC-MPS	Novartis	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolate mofetil Tab./Cap.	Mycophenolate mofetil Tab./Cap.	Chong Kun Dang Pharmaceutical	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid (Myfortic)	Mycophenolic Acid (Myfortic)	University of North Carolina, Chapel Hill	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenylate mofetil	Mycophenylate mofetil	Masonic Cancer Center, University of Minnesota	marketed	Immunosuppressant, IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid Oral Product	Mycophenolic Acid Oral Product	Simon Tremblay, PharmD, PhD	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Placebo to Mycophenolate mofetil	Placebo to Mycophenolate mofetil	Hoffmann-La Roche	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II
Mycophenolic Acid (MPA)	Mycophenolic Acid (MPA)	Novartis	marketed	Immunosuppressant; IMPDH inhibitor	Inosine monophosphate dehydrogenase (IMPDH) type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant; IMPDH inhibitor class)

Novartis · 2 drugs in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Simon Tremblay, PharmD, PhD · 1 drug in this class
University of North Carolina, Chapel Hill · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMF/EC-MPS — Competitive Intelligence Brief. https://druglandscape.com/ci/mmf-ec-mps. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab